Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Telfer

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Research Square|April 8, 2025
ADAPT-3D: Accelerated Deep Adaptable Processing of Tissue for 3-Dimensional Fluorescence Tissue Imaging for Research and Clinical SettingsDaniel D Lee, Deanna L Davis, Leon C D Smyth, et al.
Scientific Reports|August 29, 2025
ADAPT-3D:accelerated deep adaptable processing of tissue for 3-dimensional fluorescence tissue imaging for research and clinical settingsDaniel D Lee, Kevin A Telfer, Deanna L Davis, et al.
Plos One|March 3, 2018
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastomaKenny Kwok-Hei Yu, Jessica T Taylor, Omar N Pathmanaban, et al.
Bioengineering (Basel, Switzerland)|May 27, 2026
Deep Learning-Based Tracking of Neurovascular Features Toward Semi-Automated Ultrasound-Guided Peripheral Nerve Blocks by Non-SpecialistsLars A Gjesteby, Alec Carruthers, Joshua Werblin, et al.
Cancer Research Communications|December 5, 2022
Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transitionJingwei Zhang, Adam J Pearson, Nitin Sabherwal, et al.
Plos One|February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfCian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Nature|April 15, 2026
mRNA vaccines engage unconventional pathways in CD8<sup>+</sup> T cell primingSuin Jo, Lijin Li, Chandrani Thakur, et al.
Cell Reports|June 22, 2022
Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breachedDaniel J Wilcock, Andrew P Badrock, Chun W Wong, et al.
Nature Communications|September 26, 2023
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer modelsChun Wai Wong, Christos Evangelou, Kieran N Sefton, et al.
Scientific Reports|March 3, 2022
Detection of COVID-19 using multimodal data from a wearable device: results from the first TemPredict StudyAshley E Mason, Frederick M Hecht, Shakti K Davis, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Research Square|April 8, 2025
ADAPT-3D: Accelerated Deep Adaptable Processing of Tissue for 3-Dimensional Fluorescence Tissue Imaging for Research and Clinical SettingsDaniel D Lee, Deanna L Davis, Leon C D Smyth, et al.
Scientific Reports|August 29, 2025
ADAPT-3D:accelerated deep adaptable processing of tissue for 3-dimensional fluorescence tissue imaging for research and clinical settingsDaniel D Lee, Kevin A Telfer, Deanna L Davis, et al.
Plos One|March 3, 2018
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastomaKenny Kwok-Hei Yu, Jessica T Taylor, Omar N Pathmanaban, et al.
Bioengineering (Basel, Switzerland)|May 27, 2026
Deep Learning-Based Tracking of Neurovascular Features Toward Semi-Automated Ultrasound-Guided Peripheral Nerve Blocks by Non-SpecialistsLars A Gjesteby, Alec Carruthers, Joshua Werblin, et al.
Cancer Research Communications|December 5, 2022
Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transitionJingwei Zhang, Adam J Pearson, Nitin Sabherwal, et al.
Plos One|February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfCian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Nature|April 15, 2026
mRNA vaccines engage unconventional pathways in CD8<sup>+</sup> T cell primingSuin Jo, Lijin Li, Chandrani Thakur, et al.
Cell Reports|June 22, 2022
Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breachedDaniel J Wilcock, Andrew P Badrock, Chun W Wong, et al.
Nature Communications|September 26, 2023
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer modelsChun Wai Wong, Christos Evangelou, Kieran N Sefton, et al.
Scientific Reports|March 3, 2022
Detection of COVID-19 using multimodal data from a wearable device: results from the first TemPredict StudyAshley E Mason, Frederick M Hecht, Shakti K Davis, et al.
Pageof 11